drugset / Trial / NCT03868540

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

NCT03868540

Phase 1 Terminated 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.

Timeline

Start
2019-03-28
Primary completion
2019-11-25
Completion
2019-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.